QuidelOrtho

QuidelOrtho is a pure-play diagnostics leader with an 80+ year combined legacy, formed via a $6 billion merger in 2022. Its mission is to provide vital health information across the entire care continuum by leveraging a diversified technology portfolio spanning immunoassay, clinical chemistry, molecular diagnostics, and transfusion medicine. The company's strategy is to drive growth through portfolio integration, operational efficiency, and expanding its high-value informatics and service offerings to become an indispensable partner to healthcare providers globally.

A diversified portfolio of diagnostic platforms including the VITROS integrated chemistry/immunoassay systems for central labs, SOFIA and QUICKVUE for point-of-care/rapid testing, LYRA for open-platform molecular PCR, and ORTHO VISION for automated transfusion medicine.

QuidelOrtho competes with large IVD conglomerates (Roche, Abbott, Siemens) in central lab and specialized players in POC/rapid testing. Its primary advantages are its pure-play focus, unmatched breadth across the diagnostic continuum, and strong service reputation, though it faces constant pricing and innovation pressure.